Table 1.
Baseline characteristics of patients at time of inclusion.
| Last measurement before riociguat treatment | |
|---|---|
| Patients (n (%)) | 36 (100) |
| Age (years) (median (IQR)) | 62 (50–71) |
| Female (n (%)) | 14 (38.9) |
| Body mass index (kg/m2) (median (IQR)) | 24 (23–27) |
| History of VTE (n (%)) | 10 (27.8) |
| Interval between first symptoms to CTEPH diagnosis (months) (median (IQR)) | 16 (6–44) |
| Pulmonary function | |
| TLC (% pred) | 97 ± 25 |
| FVC (% pred) | 84 ± 20 |
| FEV1 (% pred) | 83 ± 22 |
| Anticoagulation | |
| Vitamin K antagonist (n (%)) | 6 (16.7) |
| FXa inhibitor (n (%)) | 30 (83.3) |
Values are given as mean ± SD unless otherwise indicated.
IQR, interquartile range; VTE, venous thromboembolism; CTEPH, chronic thromboembolic pulmonary hypertension; BPA, balloon pulmonary angioplasty; TLC, total lung capacity; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s.